We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




STI Molecular Test Delivers Rapid POC Results for Treatment Guidance

By LabMedica International staff writers
Posted on 24 Dec 2025

An affordable, rapid molecular diagnostic for sexually transmitted infections (STIs) has the potential to be globally relevant, particularly in resource-limited settings where rapid, point-of-care results can significantly impact both individual treatment and antibiotic stewardship. More...

Scout Health (Santa Clara, CA, USA) is finalizing the development of STI Scout, a rapid molecular test for detecting Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct) infections in under 30 minutes. The STI Scout test can use either first void urine or vaginal swabs, and future tests will be able to guide therapy for gonorrhea treatment based on antibiotic susceptibility. Designed for both point-of-care (POC) and over-the-counter (OTC) use, the test runs on the Scout Hub near-patient molecular platform, which enables earlier organism identification, resistance prediction, and better antimicrobial stewardship.

The Scout Hub test platform leverages a proprietary molecular chemistry that enables rapid detection of multiple pathogens in a single tube. This results in a test platform with orders-of-magnitude lower cost than commercially available clinical solutions while maintaining a sensitivity that can detect targets missed by rapid antigen tests. Because the system relies on minimal hardware and low-cost consumables, it can be manufactured and scaled efficiently. STI Scout uses the Scout Connect mobile app, which provides instructions, tracks results, and eventually will also allow patients to connect digitally to a healthcare provider.

Scout has been awarded additional funding from CARB-X to investigate a pilot in a low- or middle-income country, reflecting the platform's ability to extend high-quality molecular STI testing to resource and infrastructure-constrained settings. Expanding access to accurate molecular testing in settings where treatment is often empirical can support more appropriate therapy decisions and help reduce unnecessary antibiotic use.

"Cost is the number one barrier for adoption of rapid molecular testing in the US and abroad,” said Alex Jiao, PhD, CEO and Co-Founder of Scout. “COVID showed the limits of expensive, complex systems. Even with strong performance, their economics made sustained adoption impossible. Scout has focused on lowering cost through advances in chemistry and simplifying test design, enabling a platform that meets molecular performance requirements at a price point that supports a lasting, impactful solution."

Related Links:
Scout Health 


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.